A single-center, randomized, double-blind, placebo-controlled Phase Ia clinical study to evaluate the tolerability, safety, immunogenicity and pharmacokinetics of LQ036 via oral inhalation in healthy Chinese subjects
Latest Information Update: 10 Apr 2025
At a glance
- Drugs LQ 036 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Shanghai Novamab Biopharmaceuticals
- 10 Apr 2025 New trial record